1. Neoadjuvant Therapy for HER2-Positive Breast Cancer

2. Program Goals

3. Rationale for Neoadjuvant Therapy in Early BC

4. NOAH Trial: Study Design

6. NOAH: Secondary End Point: pCR

7. Neoadjuvant Trials With Trastuzumab: pCR

8. FDA Meta-analysis

9. Neoadjuvant Trials of Trastuzumab and/or Lapatinib

10. Neo ALTTO

11. NeoALTTO: Total pCR and by HR Status

12. NeoALTTO Efficacy: Median Follow-up More Than 3 Years

13. Conclusions From Adjuvant Setting: ALTTO Findings

14. Pertuzumab Binds to Extracellular Domain of HER2: Blocks Ligand-induced Dimerization of HER2 and HER3

15. NeoSphere: Study Design

16. NeoSphere: Efficacy

17. NeoSphere: 10 Most Common AEs With Dual Anti-HER2 Blockade (Any Grade)

18. NeoSphere Most Common AEs With Dual Anti-HER2 Blockade (Grade 3 or Higher)

19. TRYPHAENA: Neoadjuvant Trastuzumab and Pertuzumab in HER2+ Early BC: Study Design (Phase 2)

20. TRYPHAENA: End Points

21. TRYPHAENA: Cardiac Safety

22. TRYPHAENA Notable Grade 3/4 AEs

23. TRYPHAENA: pCR

24. Neoadjuvant Trials: Trastuzumab + Pertuzumab

25. FDA Approval: Pertuzumab in Neoadjuvant Treatment of HER2+ BC

26. Limitations

27. BERENICE Study Design

28. Adjuvant Pertuzumab? NCCN Recommendations*

29. Summary

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. References

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)